Business

Boehringer Inhgelheim has opened a new €120 million Respimat manufacturing facility in Sant Cugat del Vallés, Spain, near Barcelona, the company said. The 17,000 sq m plant is expected to produce 25 million units per year, over half of Respimat global annual sales. The facility will create approximately 200 new jobs. Boehringer Ingelheim Spain CEO Peter Ploeger … [Read more...] about Boehringer Ingelheim opens new Respimat manufacturing facility

Theravance Biopharma and Mylan have expanded their 2015 development and commercialization agreement for nebulized revefenacin (formerly TD-4208) to include China, Hong Kong, Macau, and Taiwan. The 2015 agreement included all markets except for China and the additional territories that have now been added. Mylan will pay Theravance $18.5 million up front and up to … [Read more...] about Theravance and Mylan add China to nebulized revefenacin agreement

Upsher-Smith Laboratories has acquired the US rights to Tosymra sumatriptan nasal spray from Dr. Reddy's Laboratories, the companies have announced. The FDA approved Dr. Reddy's subsidiary Promius Pharma's NDA for Tosymra in January 2019. The agreement, which also covered US rights to Zembrace Symtouch sumatriptan injection, included a $70 million upfront payment, … [Read more...] about Upsher-Smith acquires US rights to Tosymra sumatriptan nasal spray

Insys Therapeutics has filed for Chapter 11 bankruptcy and plans to sell "substantially all of the company’s assets," the company said. Insys's pipeline includes inhaled dronabinol, intranasal epinephrine, and intranasal naloxone. NDA submissions for the nasal sprays had been planned for 2019. The bankruptcy filing comes in the wake of legal troubles related to … [Read more...] about Insys Therapeutics files for bankruptcy, plans to sell all assets

Medical Developments International (MVP) announced that Mundipharma has acquired exclusive Australian distribution rights for the Penthrox methoxyflurane inhaler. Mundipharma already has the rights to market Penthrox in most of Europe. Mundipharma Australia and New Zealand Managing Director Jane Orr, commented, “Options for pain relief are limited in many clinical … [Read more...] about Mundipharma gets Australian rights to Penthrox

Nasal drug delivery specialist Kurve Technology announced that the US Department of Defense (DoD) has awarded the company a contract for testing a formulation for the treatment of traumatic brain injury (TBI). The Kurve ViaNase device is an electronic atomizer based on a controlled particle dispersion technology platform making use of vortical flow that … [Read more...] about Kurve Technology gets Defense Department contract for intranasal therapy for traumatic brain injury

Acerus Pharmaceuticals said that it has acquired exclusive worldwide rights to technology related to intranasal delivery of testosterone from the University of Texas at Austin. The company said that the agreement covers the use of the intranasal testosterone technology "in all applicable fields." Formerly known as Trimel, Acerus previously developed Natesto … [Read more...] about Acerus Pharmaceuticals licenses intranasal testosterone technology from UT Austin